Article
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study.
Lung cancer (Amsterdam, Netherlands) - 1 May 2025
Chouaid Christos, Bosquet Lise, Knott Craig, Li Ziming, Schaeffer Marcy, Lin Xiwu, Schioppa Claudio A, Perualila Nolen Joy, Diels Joris, Caparros Eduardo Quintero, Galea Francesca, Hultén Annika, Greystoke Alastair
Abstract excerpt
INTRODUCTION: In PAPILLON, frontline amivantamab + carboplatin + pemetrexed (ACP) demonstrated superior efficacy over carboplatin + pemetrexed in patients with advanced or metastatic non-small-cell lung cancer (aNSCLC) harboring mutations in epidermal growth factor receptor (EGFR) exon 20 insertions (exon20ins). Real-world (RW) treatment patterns and comparative effectiveness of ACP versus RW treatments are...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Male